Skerjanec Simona 4

What Happened
Simona Skerjanec, a director of Avidity Biosciences (RNAM), disposed of a total of 59,034 securities on 2026-02-27. The Form 4 lists three dispositions: 6,692 shares of common stock and two derivative dispositions of 10,034 and 42,308 units. These dispositions were made pursuant to the Agreement and Plan of Merger with Novartis; the merger consideration is $72.00 per share. Options referenced in the filing were cashed out per the merger terms (see Key Details).

Key Details

• Transaction date: 2026-02-27 (reported on Form 4 filed 2026-02-27). Filing appears timely.
• Reported counts: 6,692 common shares; 10,034 and 42,308 derivative dispositions (total 59,034). Form 4 lists prices as N/A because shares/options were disposed to the issuer under the Merger Agreement.
• Merger price: $72.00 per share (per footnotes). Implied gross consideration at $72/share ≈ $4,250,448, though option payouts equal the excess of $72 over each option’s exercise price (so actual cash received for options may differ).
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes:
  • F1: Common stock (including RSUs previously reported) disposed pursuant to the Merger Agreement.
  • F2: Options were cashed out under the Merger Agreement for a cash payment equal to the excess of the $72 merger consideration over the exercise price.
• Filing timeliness: No late filing indicator; transaction and report date are the same.

Context

• These were merger-related dispositions (not routine open-market sales). Common shares/RSUs were surrendered to the issuer in connection with the Novartis acquisition; options were settled for cash (not exercised then held).
• Such M&A cash-outs are standard corporate action outcomes and do not necessarily signal the insider’s view on the company’s standalone near-term prospects.